The nanotechnology drug delivery market was valued for $87.5 billion in 2022 and is estimated to reach $209.5 billion by 2032, exhibiting a CAGR of 9.1% from 2023 to 2032. Nanotechnology is a scientific field that involves manipulating matter at the nanoscale, which is the scale of atoms and molecules. It explores the unique properties and behaviors of materials at this tiny scale and seeks to harness them for various applications. One significant area where nanotechnology has made remarkable strides is in drug delivery. In drug delivery, nanotechnology offers the potential to revolutionize the way medications are administered, enhancing their effectiveness, and minimizing side effects. Nanoparticles, typically ranging from 1 to 100 nanometers in size, are designed and engineered to encapsulate therapeutic drugs.
The nanotechnology drug delivery market is driven by rise in prevalence of chronic diseases, and advancements in nanotechnology. The rise in prevalence of chronic diseases has emerged as a major driver for the nanotechnology drug delivery market. Chronic diseases, such as cancer, diabetes, cardiovascular diseases, and respiratory disorders, continue to pose significant health challenges globally. According to International Diabetes Federation, in 2021, it was estimated that approximately 537 million people were living with diabetes. Furthermore, according to the same source, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. For instance, researchers from Monash University, RMIT University, The University of Melbourne and the Baker Institute developed a system that responds to glucose, which current insulin does not.
The preclinical study engineered a superior artificial pancreas system to release insulin only when it is genuinely required by the body, resulting in a more dependable regulation of blood glucose levels. This innovative nano sugar platform facilitated prompt and consistent insulin delivery that responded to glucose levels, surpassing other systems in terms of duration and intelligence. The unique capabilities of nanotechnology in enhancing drug delivery precision, targeting, and personalized medicine have positioned it as a promising solution to address the challenges associated with chronic disease management. Thus, the rise in prevalence of chronic diseases has become a key driving force behind the growth of the nanotechnology drug delivery market.
Furthermore, technological advancements in nanomedicines are expected to play a significant role in the growth of the nanotechnology drug delivery market. The limitations of traditional drug delivery systems (DDSs) have led to a significant rise in the popularity of nanocarriers. For instance, scientists at Arizona State University have created an 'origami nanorobot' known as such due to its ability to transform into different forms. It comprises a flat synthetic DNA sheet coated with a blood-clotting enzyme. Once injected into the bloodstream, the nanoscale DNA sheet is designed to locate tumor cells, bind to their surface, and introduce the blood-clotting enzyme, effectively depriving the tumor cell of the necessary blood supply for its survival.
This tiny robot addresses a challenging aspect of cancer treatment, which involves eradicating cancer cells while minimizing damage to nearby healthy tissue. However, manufacturing complexities might act as a restraint for the growth of the market. On the other hand, government initiatives such as funding to encourage research activities are expected to serve as growth opportunity in the nanotechnology drug delivery market. The nanotechnology drug delivery market is segmented on the basis of formulation, application, and region. formulation, the market is categorized into lipid-based nanomedicine, polymer-based nanomedicine, nanocrystals, and others.
The others Include inorganic nanoparticles, protein-based nanoparticles, and micelles. On the basis of application, the market is categorized into oncology & hematology, infectious diseases, orthopedics, neurology, urology, immunology, and others. The others Include gastrointestinal, inflammatory, endocrine, integumentary ophthalmology, and cardiology.
On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). The key players that operate in the global nanotechnology drug delivery market are AbbVie Inc, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Amgen Inc, Merck KGaA, Nanobiotix SA, Novartis AG, Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Limited.
The nanotechnology drug delivery market is driven by rise in prevalence of chronic diseases, and advancements in nanotechnology. The rise in prevalence of chronic diseases has emerged as a major driver for the nanotechnology drug delivery market. Chronic diseases, such as cancer, diabetes, cardiovascular diseases, and respiratory disorders, continue to pose significant health challenges globally. According to International Diabetes Federation, in 2021, it was estimated that approximately 537 million people were living with diabetes. Furthermore, according to the same source, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. For instance, researchers from Monash University, RMIT University, The University of Melbourne and the Baker Institute developed a system that responds to glucose, which current insulin does not.
The preclinical study engineered a superior artificial pancreas system to release insulin only when it is genuinely required by the body, resulting in a more dependable regulation of blood glucose levels. This innovative nano sugar platform facilitated prompt and consistent insulin delivery that responded to glucose levels, surpassing other systems in terms of duration and intelligence. The unique capabilities of nanotechnology in enhancing drug delivery precision, targeting, and personalized medicine have positioned it as a promising solution to address the challenges associated with chronic disease management. Thus, the rise in prevalence of chronic diseases has become a key driving force behind the growth of the nanotechnology drug delivery market.
Furthermore, technological advancements in nanomedicines are expected to play a significant role in the growth of the nanotechnology drug delivery market. The limitations of traditional drug delivery systems (DDSs) have led to a significant rise in the popularity of nanocarriers. For instance, scientists at Arizona State University have created an 'origami nanorobot' known as such due to its ability to transform into different forms. It comprises a flat synthetic DNA sheet coated with a blood-clotting enzyme. Once injected into the bloodstream, the nanoscale DNA sheet is designed to locate tumor cells, bind to their surface, and introduce the blood-clotting enzyme, effectively depriving the tumor cell of the necessary blood supply for its survival.
This tiny robot addresses a challenging aspect of cancer treatment, which involves eradicating cancer cells while minimizing damage to nearby healthy tissue. However, manufacturing complexities might act as a restraint for the growth of the market. On the other hand, government initiatives such as funding to encourage research activities are expected to serve as growth opportunity in the nanotechnology drug delivery market. The nanotechnology drug delivery market is segmented on the basis of formulation, application, and region. formulation, the market is categorized into lipid-based nanomedicine, polymer-based nanomedicine, nanocrystals, and others.
The others Include inorganic nanoparticles, protein-based nanoparticles, and micelles. On the basis of application, the market is categorized into oncology & hematology, infectious diseases, orthopedics, neurology, urology, immunology, and others. The others Include gastrointestinal, inflammatory, endocrine, integumentary ophthalmology, and cardiology.
On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). The key players that operate in the global nanotechnology drug delivery market are AbbVie Inc, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Amgen Inc, Merck KGaA, Nanobiotix SA, Novartis AG, Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nanotechnology drug delivery market analysis from 2022 to 2032 to identify the prevailing nanotechnology drug delivery market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the nanotechnology drug delivery market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global nanotechnology drug delivery market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Formulation
- Lipid-based nanomedicine
- Polymer-based nanomedicine
- Nanocrystals
- Others
By Application
- Oncology and Hematology
- Infectious diseases
- Orthopedics
- Neurology
- Urology
- Immunology
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbvie Inc
- Amgen Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Merck KGaA
- Nanobiotix SA
- Novartis AG
- Pfizer Ltd
- Teva Pharmaceutical Industries Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION
CHAPTER 5: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION
CHAPTER 6: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Nanotechnology Drug Delivery Market,' The nanotechnology drug delivery market was valued at $87.5 billion in 2022, and is estimated to reach $209.5 billion by 2032, growing at a CAGR of 9.1% from 2023 to 2032. Nanotechnology has revolutionized the field of drug delivery by offering innovative solutions to overcome challenges in targeted therapy, enhanced drug efficacy, and improved patient outcomes. The nanotechnology-based drug delivery market has witnessed significant growth and holds immense potential for the future of medicine. Nanoparticles, nano emulsions, and nanocarriers are some of the key components of nanotechnology used in drug delivery systems. These nanoscale structures possess unique physicochemical properties, such as a high surface area-to-volume ratio and the ability to encapsulate and deliver therapeutic agents to specific target sites in the body.Key factors driving the growth of the nanotechnology drug delivery market due to rise in prevalence of cancer, cardiovascular and neurological disease, and increase in demand for nanotechnology drug delivery. Chronic diseases such as cancer, diabetes, cardiovascular disorders, and neurological conditions have become increasingly prevalent worldwide, posing substantial healthcare challenges. According to British Heart Foundation, as of 2023, it is estimated that around 620 million people living with heart and circulatory diseases globally. Furthermore, according to same source, in 2021, heart and circulatory diseases cause around 1 in 3 deaths globally. Nanoparticles are particularly well-suited for the examination and advancement of potential treatments for cardiovascular diseases (CVD) due to their size, controllable properties, and capacity to integrate therapeutic and imaging methods. According to a 2023 study report by National Library of Medicines, it was reported that through the use of nanotechnology, more than 50% of CVDs may be treated efficiently. Heart-targeted nano carrier-based drug delivery is an effective and efficient approach for treating cardiac-related disorders such as atherosclerosis, hypertension, and myocardial infarction. Thus, the rise in prevalence of chronic diseases is expected to result in high demand of nanomedicines owing to its more efficient therapeutic effect and less side effects.
In addition, growth in awareness among the population regarding neurological disorders has played a significant role in driving the nanotechnology drug delivery market. For instance, Vaxxas Pty Ltd, a biotechnology company, has developed a platform called ‘Nanopatch’ that utilizes lipid nanoparticle-coated projections to deliver vaccines directly to immune cells in the skin, potentially improving vaccine efficacy and eliminating the need for refrigeration during distribution. In March 2023, Vaxxas Pty Ltd reported positive phase 1 results from nanopatch. Furthermore, In March 2023, researchers at Hokkaido University in Japan developed a new delivery system for CRISPR-Cas9 based on lipid nanoparticles (LNPs), which significantly increases the efficiency of in vivo gene therapy.
The market also offers growth opportunities to the key players in the market. Government initiatives have the potential to act as significant growth opportunities in the field of nanotechnology drug delivery. Through funding and grants, governments may provide financial support to academic institutions, research organizations, and companies involved in nanotechnology drug delivery research and development. This financial assistance encourages exploration into new drug delivery technologies and the development of innovative nanomaterials, translating research findings into commercial applications. For instance, Ministry of Electronics and Information Technology (MeitY) India, has taken several major initiatives for the promotion of Nanoelectronics research and innovation in the country. Major Nanoelectronics Centers of international standards have been established at premier institutes in the country.
The nanotechnology drug delivery market is segmented into formulation, application and region. On the basis of formulation, the market is classified into lipid-based nanomedicine, polymer-based nanomedicine, nanocrystals and others. The others include inorganic nanoparticles, protein-based nanoparticles, and micelles. On the basis of application, the market is categorized into oncology & hematology, infectious diseases, orthopedics, neurology, urology, immunology, and others. The others include gastrointestinal, inflammatory, endocrine, integumentary ophthalmology, and cardiology.
- Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include AbbVie Inc, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Amgen Inc, Merck KGaA, Nanobiotix SA, Novartis AG, Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Limited
Key Market Insights (Updated)
- By formulation, the polymer-based nanomedicine segment was the highest revenue contributor, whereas lipid-based nanomedicine is anticipated to grow at the highest CAGR of 9.7% during the forecast period
- By application, the oncology and hematology segment was the highest revenue contributor, whereas neurology is anticipated to grow at the highest CAGR of 11.4% during the forecast period
- Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 10.3% during the forecast period
Companies Mentioned
- Abbvie Inc
- Amgen Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Merck KGaA
- Nanobiotix SA
- Novartis AG
- Pfizer Ltd
- Teva Pharmaceutical Industries Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
